Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Dysregulation of endocannabinoid concentrations in human subcutaneous adipose tissue in obesity and modulation by omega-3 polyunsaturated fatty acids

HL. Fisk, CE. Childs, EA. Miles, R. Ayres, PS. Noakes, C. Paras-Chavez, O. Kuda, J. Kopecký, E. Antoun, KA. Lillycrop, PC. Calder

. 2021 ; 135 (1) : 185-200. [pub] 20210115

Language English Country Great Britain

Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026195

Obesity is believed to be associated with a dysregulated endocannabinoid system which may reflect enhanced inflammation. However, reports of this in human white adipose tissue (WAT) are limited and inconclusive. Marine long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) have anti-inflammatory actions and therefore may improve obesity-associated adipose tissue inflammation. Therefore, fatty acid (FA) concentrations, endocannabinoid concentrations, and gene expression were assessed in subcutaneous WAT (scWAT) biopsies from healthy normal weight individuals (BMI 18.5-25 kg/m2) and individuals living with metabolically healthy obesity (BMI 30-40 kg/m2) prior to and following a 12-week intervention with 3 g fish oil/day (1.1 g eicosapentaenoic acid (EPA) + 0.8 g DHA) or 3 g corn oil/day (placebo). WAT from individuals living with metabolically healthy obesity had higher n-6 PUFAs and EPA, higher concentrations of two endocannabinoids (anandamide (AEA) and eicosapentaenoyl ethanolamide (EPEA)), higher expression of phospholipase A2 Group IID (PLA2G2D) and phospholipase A2 Group IVA (PLA2G4A), and lower expression of CNR1. In response to fish oil intervention, WAT EPA increased to a similar extent in both BMI groups, and WAT DHA increased by a greater extent in normal weight individuals. WAT EPEA and docosahexaenoyl ethanolamide (DHEA) increased in normal weight individuals only and WAT 2-arachidonyl glycerol (2-AG) decreased in individuals living with metabolically healthy obesity only. Altered WAT fatty acid, endocannabinoid, and gene expression profiles in metabolically healthy obesity at baseline may be linked. WAT incorporates n-3 PUFAs when their intake is increased which affects the endocannabinoid system; however, effects appear greater in normal weight individuals than in those living with metabolically healthy obesity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026195
003      
CZ-PrNML
005      
20211026133126.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1042/CS20201060 $2 doi
035    __
$a (PubMed)33393630
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Fisk, Helena L $u School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
245    10
$a Dysregulation of endocannabinoid concentrations in human subcutaneous adipose tissue in obesity and modulation by omega-3 polyunsaturated fatty acids / $c HL. Fisk, CE. Childs, EA. Miles, R. Ayres, PS. Noakes, C. Paras-Chavez, O. Kuda, J. Kopecký, E. Antoun, KA. Lillycrop, PC. Calder
520    9_
$a Obesity is believed to be associated with a dysregulated endocannabinoid system which may reflect enhanced inflammation. However, reports of this in human white adipose tissue (WAT) are limited and inconclusive. Marine long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) have anti-inflammatory actions and therefore may improve obesity-associated adipose tissue inflammation. Therefore, fatty acid (FA) concentrations, endocannabinoid concentrations, and gene expression were assessed in subcutaneous WAT (scWAT) biopsies from healthy normal weight individuals (BMI 18.5-25 kg/m2) and individuals living with metabolically healthy obesity (BMI 30-40 kg/m2) prior to and following a 12-week intervention with 3 g fish oil/day (1.1 g eicosapentaenoic acid (EPA) + 0.8 g DHA) or 3 g corn oil/day (placebo). WAT from individuals living with metabolically healthy obesity had higher n-6 PUFAs and EPA, higher concentrations of two endocannabinoids (anandamide (AEA) and eicosapentaenoyl ethanolamide (EPEA)), higher expression of phospholipase A2 Group IID (PLA2G2D) and phospholipase A2 Group IVA (PLA2G4A), and lower expression of CNR1. In response to fish oil intervention, WAT EPA increased to a similar extent in both BMI groups, and WAT DHA increased by a greater extent in normal weight individuals. WAT EPEA and docosahexaenoyl ethanolamide (DHEA) increased in normal weight individuals only and WAT 2-arachidonyl glycerol (2-AG) decreased in individuals living with metabolically healthy obesity only. Altered WAT fatty acid, endocannabinoid, and gene expression profiles in metabolically healthy obesity at baseline may be linked. WAT incorporates n-3 PUFAs when their intake is increased which affects the endocannabinoid system; however, effects appear greater in normal weight individuals than in those living with metabolically healthy obesity.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a kyseliny arachidonové $x metabolismus $7 D001095
650    12
$a potravní doplňky $7 D019587
650    _2
$a kyseliny dokosahexaenové $x aplikace a dávkování $7 D004281
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a kyselina eikosapentaenová $x aplikace a dávkování $7 D015118
650    _2
$a endokanabinoidy $x metabolismus $7 D063388
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fosfolipasy A2, skupina II $x metabolismus $7 D054501
650    _2
$a fosfolipasy A2, skupina IV $x metabolismus $7 D054513
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metabolicky zdravá obezita $x diagnóza $x farmakoterapie $x metabolismus $7 D000067329
650    _2
$a polynenasycené alkamidy $x metabolismus $7 D053284
650    _2
$a receptor kanabinoidní CB1 $x metabolismus $7 D043884
650    _2
$a podkožní tuk $x účinky léků $x metabolismus $7 D050151
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Anglie $7 D004739
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Childs, Caroline E $u School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom $u Institute for Life Sciences, University of Southampton, Southampton, United Kingdom
700    1_
$a Miles, Elizabeth A $u School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
700    1_
$a Ayres, Robert $u School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
700    1_
$a Noakes, Paul S $u School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
700    1_
$a Paras-Chavez, Carolina $u School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
700    1_
$a Kuda, Ondrej $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kopecký, Jan $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Antoun, Elie $u School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
700    1_
$a Lillycrop, Karen A $u School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom $u Institute for Life Sciences, University of Southampton, Southampton, United Kingdom $u School of Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, United Kingdom
700    1_
$a Calder, Philip C $u School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom $u Institute for Life Sciences, University of Southampton, Southampton, United Kingdom $u NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom
773    0_
$w MED00009494 $t Clinical science (London, England : 1979) $x 1470-8736 $g Roč. 135, č. 1 (2021), s. 185-200
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33393630 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133132 $b ABA008
999    __
$a ok $b bmc $g 1715031 $s 1146702
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 135 $c 1 $d 185-200 $e 20210115 $i 1470-8736 $m Clinical science (1979) $n Clin Sci (Lond) $x MED00009494
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options